Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

McGill University

$40,000.00

Nanoplexes for biological therapies

EF 2012-13

Résumé
Potent ""drug delivery systems"" are required to meet the specifications of ""biologically-derived"" drug delivery in the field of biological therapy. Biological therapy, i. e the delivery of nucleic acids (DNAs, RNAs), protein and peptides to the cell using non-viral vehicles, as well as cells delivery to the site of interest, are promising avenues for effective treatment of many genetic and chronic diseases. Traditional biomaterials for biological therapy are essentially ""borrowed"" from conventional drug delivery systems. Despite the development of various micro/nano particulate carrier systems, the final outcomes of biological therapy remain modest. This is attributed to poor understanding of the underlying mechanisms governing cellular uptake and intracellular trafficking of carrier systems. Through our work, we employ combinatorial approaches to introduce new features into nanocarrier systems to improve their structural diversity and interactions with cells and biological molecules. The overall aim of our research in the field of controlled delivery of ""biologically-derived"" drugs is to develop multifunctional nanoplexes possessing both targeting and tracking capabilities to overcome limitations of biological therapies, examining the internalisation process and fate of the delivery vehicle and its cellular cargo. More specifically, we propose to develop multifunctional gene delivery vehicles based on chitosan derivatives for use in vascular repair and treatment of atherosclerosis. Three approaches are proposed: 1) Photo-labile nanoplexes for delivery of genetic materials to endothelial cells for correlative imaging; 2) Core-shell Estradiol nanoparticle delivery systems targeting endothelial progenitor cells; and 3) Multifunctional nanoplex gene inhibitory systems promoting endothelial progenitor cell differentiation to mature endothelium. According to the Can. J. Cardiology (October 2010, 26(8):e297-e305), cardiovascular diseases account for 30% of deaths in Canada. The economic burden associated with atherothrombosis for Canadians, including physician services, hospitalizations, lost wages and decreased productivity, totals $22.2 billion annually. Our success in this research could provide instant relief to health care systems both within Canada and globally.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
218072-2011
Name nom
Tabrizian, Maryam
Department département
Biomedical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2011
Award amount
40000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
2
Nb partie
5
Application title
Nanoplexes for biological therapies
Keyword
NSERC
Application summary
Potent ""drug delivery systems"" are required to meet the specifications of ""biologically-derived"" drug delivery in the field of biological therapy. Biological therapy, i. e the delivery of nucleic acids (DNAs, RNAs), protein and peptides to the cell using non-viral vehicles, as well as cells delivery to the site of interest, are promising avenues for effective treatment of many genetic and chronic diseases. Traditional biomaterials for biological therapy are essentially ""borrowed"" from conventional drug delivery systems. Despite the development of various micro/nano particulate carrier systems, the final outcomes of biological therapy remain modest. This is attributed to poor understanding of the underlying mechanisms governing cellular uptake and intracellular trafficking of carrier systems. Through our work, we employ combinatorial approaches to introduce new features into nanocarrier systems to improve their structural diversity and interactions with cells and biological molecules. The overall aim of our research in the field of controlled delivery of ""biologically-derived"" drugs is to develop multifunctional nanoplexes possessing both targeting and tracking capabilities to overcome limitations of biological therapies, examining the internalisation process and fate of the delivery vehicle and its cellular cargo. More specifically, we propose to develop multifunctional gene delivery vehicles based on chitosan derivatives for use in vascular repair and treatment of atherosclerosis. Three approaches are proposed: 1) Photo-labile nanoplexes for delivery of genetic materials to endothelial cells for correlative imaging; 2) Core-shell Estradiol nanoparticle delivery systems targeting endothelial progenitor cells; and 3) Multifunctional nanoplex gene inhibitory systems promoting endothelial progenitor cell differentiation to mature endothelium. According to the Can. J. Cardiology (October 2010, 26(8):e297-e305), cardiovascular diseases account for 30% of deaths in Canada. The economic burden associated with atherothrombosis for Canadians, including physician services, hospitalizations, lost wages and decreased productivity, totals $22.2 billion annually. Our success in this research could provide instant relief to health care systems both within Canada and globally.